Transforming Cancer Care with

SPOT ON Precision Diagnostics

Exciting News!

DiaCarta’s RadTox™ Test to Monitor Tumor Response Receives Medicare Coverage

Press Release

DiaCarta Launches OTC at Home Fecal Occult Blood Test to Complement its ColoScape™ Test

Media Coverage by Genomeweb

SARS-CoV-2 Delta Variant PCR Could Help Surveillance Efforts, Developers Say

Media Coverage by genomeweb

DiaCarta Positioning Liquid Biopsy Assay

to Gauge Chemotherapy Response

in Multiple Cancers

Press Release

DiaCarta’s RadTox™ Test to Monitor Tumor Response Receives Medicare Coverage

Press Release

DiaCarta Announces Successful Completion of Oncuria® Validation Study with Nonagen Bioscience

Media Coverage by genomeweb

SARS-CoV-2 Delta Variant PCR Could Help Surveillance Efforts, Developers Say

Media Coverage by genomeweb

DiaCarta Positioning Liquid Biopsy Assay to Gauge Chemotherapy Response in Multiple Cancers

DiaCarta is a leading precision diagnostic company specializing in providing comprehensive one-stop-shop for cancer patient management solutions.

1

Early Detection/Screening

2

Diagnosis

3

Therapy Selection

4

Therapy Monitoring

Our offerings

Our proprietary XNA technology and isobDNA™ technology allow for sensitive, accurate, and cost-effective detection of genetic alterations using different genomic platforms, positioning us as a leader in the precision diagnostic industry.

Our suite of diagnostic products and services, including RadTox™, ColoScape™, and Oncuria®, along with our range of infectious disease tests, such as HPV tests and MonkeyPox tests, deliver superior clinical performance and economic value to healthcare providers and patients worldwide.

OTC/POC Tests and Accessories

Global Expansion

Our team of world-class scientists, clinicians, and industry experts is dedicated to advancing precision medicine through continued investment in research and development, strategic partnerships, and global expansion.

ISO 13485 certified GMP manufacturing facility

Based in California, USA, with global subsidiaries in Europe and Asia

Innovative R&D lab

CAP-accredited CLIA lab

Affordable Excellence with Unmatched Sensitivity and Specificity

XNA Technology

Current genomics technology has improved a lot. We can now detect genetic/somatic mutations in tissue samples (biopsy) and even in body fluids (liquid biopsy). Still, it is tough to find rare genetic changes, especially those in early-stage cancer or residual cancer cells (MRD, or Molecular Residual Disease, monitoring).

XNA technology solves this problem by boosting sensitivity and specificity in traditional platforms like Sanger sequencing, qPCR, ddPCR, and NGS, without changing the existing protocol.

High-throughput and sensitive mutation detection and quantification capability without DNA sequencing

isobDNA™ Technology

Tools like qPCR and ddPCR are often used to quantify gene copy number and gene expression. But, to get accurate results, we first need to extract and purify the DNA or RNA from samples. The problem is, during the extraction, we will lose some DNA or RNA. This becomes a big concern when we only have a small amount of samples to start with.

isobDNA™ technology solves the problem because it does require the sample extraction process. Instead of amplifying the targets like PCR technology, isobDNA technology amplifies the signals. It’s just as sensitive as PCR but more accurate.

Who should be tested for VEXAS syndrome?

As a relatively newly discovered autoinflammatory disease, VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is associated with mutations in the UBA1 gene. Diagnosis of the disease relies on the testing of genetic mutation in patients. What are...

Genetic Testing for the VEXAS Syndrome

Diagnosis of the VEXAS syndrome improves medical management of the disease and provides more effective treatment of the disease, although there is no cure currently. The diagnosis relies on the VEXAS syndrome genetic testing, a test for a mutation present in the UBA1...

X